Published in Calcif Tissue Int on February 15, 2011
Bisphosphonates and bone quality. Bonekey Rep (2014) 0.85
Kinsenoside prevents ovariectomy-induced bone loss and suppresses osteoclastogenesis by regulating classical NF-κB pathways. Osteoporos Int (2012) 0.82
Inhibition of osteocyte apoptosis prevents the increase in osteocytic receptor activator of nuclear factor κB ligand (RANKL) but does not stop bone resorption or the loss of bone induced by unloading. J Biol Chem (2015) 0.80
Advanced glycation end products play adverse proinflammatory activities in osteoporosis. Mediators Inflamm (2014) 0.79
Effect of age on regulation of human osteoclast differentiation. J Cell Biochem (2014) 0.78
Vitamin D metabolism and action in human marrow stromal cells: effects of chronic kidney disease. J Steroid Biochem Mol Biol (2012) 0.77
Serum carcinoembryonic antigen-related cell adhesion molecule 1 level in postmenopausal women: correlation with β-catenin and bone mineral density. Osteoporos Int (2015) 0.75
Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med (1995) 10.99
Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med (2004) 8.86
TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest (2000) 5.78
Minireview: the OPG/RANKL/RANK system. Endocrinology (2001) 4.47
Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med (2009) 4.39
Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res (1998) 3.65
Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther (2001) 3.59
Alendronate for the treatment of osteoporosis in men. N Engl J Med (2000) 3.11
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest (2003) 3.09
Age-related intrinsic changes in human bone-marrow-derived mesenchymal stem cells and their differentiation to osteoblasts. Aging Cell (2008) 3.08
Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A (1999) 2.66
Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab (2000) 2.34
Bisphosphonates: mode of action and pharmacology. Pediatrics (2007) 2.25
Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest (1989) 1.79
Effects of human recombinant CSF-GM and highly purified CSF-1 on the formation of multinucleated cells with osteoclast characteristics in long-term bone marrow cultures. J Bone Miner Res (1986) 1.64
Formation of multinucleated cells that respond to osteotropic hormones in long term human bone marrow cultures. Endocrinology (1987) 1.46
The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology (2000) 1.43
Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun (2002) 1.35
Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res (1999) 1.33
Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. Osteoporos Int (2000) 1.27
Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers. J Clin Endocrinol Metab (1997) 1.25
Macrophage colony-stimulating factor induces substantial osteoclast generation and bone resorption in human bone marrow cultures. Blood (1996) 1.10
In vitro secretion of cytokines by human bone marrow: effects of age and estrogen status. J Clin Endocrinol Metab (1998) 1.06
Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. Br J Cancer (2001) 1.00
Interleukin-32 promotes osteoclast differentiation but not osteoclast activation. PLoS One (2009) 0.99
The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). J Bone Miner Res (2004) 0.96
Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2. Biochem Biophys Res Commun (2005) 0.96
Human osteoclast formation and activity in vitro: effects of alendronate. J Bone Miner Res (1998) 0.96
Osteoprotegerin differentially regulates protease expression in osteoclast cultures. Biochem Biophys Res Commun (2002) 0.93
Adrenal and gonadal steroids inhibit IL-6 secretion by human marrow cells. Cytokine (2001) 0.92
Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women. J Bone Miner Res (2008) 0.92
Age-related decline in osteoprotegerin expression by human bone marrow cells cultured in three-dimensional collagen sponges. Biochem Biophys Res Commun (2000) 0.92
Effects of macrophage colony stimulating factor and granulocyte-macrophage colony stimulating factor on osteoclastic differentiation of hematopoietic progenitor cells. Stem Cells (1993) 0.90
Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium. J Cell Physiol (2005) 0.89
Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. Osteoporos Int (2006) 0.89
Effects of age and gender on WNT gene expression in human bone marrow stromal cells. J Cell Biochem (2009) 0.88
Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone. Bone (2006) 0.87
Influence of age on human marrow. Calcif Tissue Int (1995) 0.86
Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression. Exp Mol Med (2002) 0.86
The deceiving appearances of osteoclasts. N Engl J Med (2009) 0.82
Effect of alendronate treatment on the osteoclastogenic potential of bone marrow cells in mice. Bone (1997) 0.82
Osteoclastogenic potential of bone marrow cells increases with age in elderly women with fracture. Mech Ageing Dev (2002) 0.80
Down-regulation of osteoprotegerin production in bone marrow macrophages by macrophage colony-stimulating factor. Cytokine (2005) 0.80
Age-related changes in cortical bone content of insulin-like growth factor binding protein (IGFBP)-3, IGFBP-5, osteoprotegerin, and calcium in postmenopausal osteoporosis: a cross-sectional study. J Clin Endocrinol Metab (2003) 0.79
The inhibitory effect of bisphosphonates on glucocorticoid-induced RANKL expression in human cells. Scand J Rheumatol (2006) 0.78
1,25(OH)2D3 and calcipotriol (MC903) have similar effects on the induction of osteoclast-like cell formation in human bone marrow cultures. Biochem Biophys Res Commun (1990) 0.77
Age-related intrinsic changes in human bone-marrow-derived mesenchymal stem cells and their differentiation to osteoblasts. Aging Cell (2008) 3.08
Factors associated with 5-year risk of hip fracture in postmenopausal women. JAMA (2007) 2.81
Serum 25-hydroxyvitamin D concentrations and risk for hip fractures. Ann Intern Med (2008) 2.44
Effects of 4 weight-loss diets differing in fat, protein, and carbohydrate on fat mass, lean mass, visceral adipose tissue, and hepatic fat: results from the POUNDS LOST trial. Am J Clin Nutr (2012) 1.96
Does obesity really make the femur stronger? BMD, geometry, and fracture incidence in the women's health initiative-observational study. J Bone Miner Res (2009) 1.71
Predictors of serum 25-hydroxyvitamin D concentrations among postmenopausal women: the Women's Health Initiative Calcium plus Vitamin D clinical trial. Am J Clin Nutr (2010) 1.67
Cooperation between TGF-beta and Wnt pathways during chondrocyte and adipocyte differentiation of human marrow stromal cells. J Bone Miner Res (2003) 1.51
Cell-free and cell-based approaches for bone regeneration. Nat Rev Rheumatol (2009) 1.46
Activating antibodies to the calcium-sensing receptor in two patients with autoimmune hypoparathyroidism. J Clin Endocrinol Metab (2004) 1.44
Osteoporosis and vitamin-D deficiency among postmenopausal women with osteoarthritis undergoing total hip arthroplasty. J Bone Joint Surg Am (2003) 1.35
Hyponatremia in marathon runners due to inappropriate arginine vasopressin secretion. Am J Med (2007) 1.29
Hypoxia inhibition of adipocytogenesis in human bone marrow stromal cells requires transforming growth factor-beta/Smad3 signaling. J Biol Chem (2005) 1.24
Calcium plus vitamin D supplementation and the risk of postmenopausal weight gain. Arch Intern Med (2007) 1.22
Vitamin D metabolism and action in human bone marrow stromal cells. Endocrinology (2009) 1.16
Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: a randomized trial. J Clin Endocrinol Metab (2002) 1.14
MicroRNA profiling reveals age-dependent differential expression of nuclear factor κB and mitogen-activated protein kinase in adipose and bone marrow-derived human mesenchymal stem cells. Stem Cell Res Ther (2011) 1.06
FRAX facts. J Bone Miner Res (2009) 1.06
Central nervous system agents for ischemic stroke: neuroprotection mechanisms. Cent Nerv Syst Agents Med Chem (2011) 1.06
Effects of 25-hydroxyvitamin D(3) on proliferation and osteoblast differentiation of human marrow stromal cells require CYP27B1/1α-hydroxylase. J Bone Miner Res (2011) 1.05
Systemically administered rhBMP-2 promotes MSC activity and reverses bone and cartilage loss in osteopenic mice. J Cell Biochem (2002) 1.02
Clinical characteristics influence in vitro action of 1,25-dihydroxyvitamin D(3) in human marrow stromal cells. J Bone Miner Res (2012) 1.00
N-acetyl-serotonin offers neuroprotection through inhibiting mitochondrial death pathways and autophagic activation in experimental models of ischemic injury. J Neurosci (2014) 1.00
Age-related decline in osteoblastogenesis and 1α-hydroxylase/CYP27B1 in human mesenchymal stem cells: stimulation by parathyroid hormone. Aging Cell (2011) 0.99
Increased longevity of hematopoiesis in continuous bone marrow cultures and adipocytogenesis in marrow stromal cells derived from Smad3(-/-) mice. Exp Hematol (2005) 0.99
Hydrostatic fluid pressure enhances matrix synthesis and accumulation by bovine chondrocytes in three-dimensional culture. J Cell Physiol (2002) 0.98
Distribution and correlates of serum 25-hydroxyvitamin D levels in a sample of patients with hip fracture. Am J Geriatr Pharmacother (2007) 0.97
The melatonin MT1 receptor axis modulates mutant Huntingtin-mediated toxicity. J Neurosci (2011) 0.96
Premature ovarian failure and body composition changes with adjuvant chemotherapy for breast cancer. Menopause (2011) 0.95
Effects of age on parathyroid hormone signaling in human marrow stromal cells. Aging Cell (2011) 0.95
The relationship between focal erosions and generalized osteoporosis in postmenopausal women with rheumatoid arthritis. Arthritis Rheum (2009) 0.94
Demineralized bone promotes chondrocyte or osteoblast differentiation of human marrow stromal cells cultured in collagen sponges. Cell Tissue Bank (2005) 0.93
Chondrocyte gene expression in osteoarthritis: Correlation with disease severity. J Orthop Res (2006) 0.91
Small molecule GS-nitroxide ameliorates ionizing irradiation-induced delay in bone wound healing in a novel murine model. In Vivo (2010) 0.91
Forum on aging and skeletal health: summary of the proceedings of an ASBMR workshop. J Bone Miner Res (2011) 0.90
A minipig model of maxillary distraction osteogenesis. J Oral Maxillofac Surg (2010) 0.90
Comparison of TGF-beta/BMP pathways signaled by demineralized bone powder and BMP-2 in human dermal fibroblasts. J Bone Miner Res (2004) 0.88
Effects of age and gender on WNT gene expression in human bone marrow stromal cells. J Cell Biochem (2009) 0.88
Adipocyte differentiation in Sod2(-/-) and Sod2(+/+) murine bone marrow stromal cells is associated with low antioxidant pools. Exp Hematol (2005) 0.88
Phenotypic analysis of bovine chondrocytes cultured in 3D collagen sponges: effect of serum substitutes. Cell Tissue Bank (2005) 0.87
Drug insight: Existing and emerging therapies for osteoporosis. Nat Clin Pract Endocrinol Metab (2006) 0.86
Diminished interleukin-6 response to proinflammatory challenge in men and women after intravenous cocaine administration. J Clin Endocrinol Metab (2003) 0.85
Inhibition of adipocytogenesis by canonical WNT signaling in human mesenchymal stem cells. Exp Cell Res (2011) 0.84
Vitamin D metabolism in human bone marrow stromal (mesenchymal stem) cells. Metabolism (2013) 0.83
The American Academy of Orthopaedic Surgeons Evidence-Based Guideline on Management of Hip Fractures in the Elderly. J Bone Joint Surg Am (2015) 0.83
Low oxygen tension enhances chondroinduction by demineralized bone matrix in human dermal fibroblasts in vitro. Cells Tissues Organs (2005) 0.83
Underestimated fracture probability in patients with unilateral hip osteoarthritis as calculated by FRAX. J Clin Densitom (2011) 0.82
The deceiving appearances of osteoclasts. N Engl J Med (2009) 0.82
Autologous cranial particulate bone graft: an experimental study of onlay cranioplasty. J Craniofac Surg (2011) 0.81
Histone deacetylation mediates the rejuvenation of osteoblastogenesis by the combination of 25(OH)D3 and parathyroid hormone in MSCs from elders. J Steroid Biochem Mol Biol (2012) 0.81
Suppression of homeobox transcription factor VentX promotes expansion of human hematopoietic stem/multipotent progenitor cells. J Biol Chem (2012) 0.81
Hip geometry in diabetic women: implications for fracture risk. Metabolism (2012) 0.81
Effect of dietary composition of weight loss diets on high-sensitivity c-reactive protein: the Randomized POUNDS LOST trial. Obesity (Silver Spring) (2013) 0.80
Histological differences in iliac and tibial bone graft. Foot Ankle Int (2010) 0.80
New chondrocyte genes discovered by representational difference analysis of chondroinduced human fibroblasts. Cells Tissues Organs (2004) 0.79
2008 Santa Fe Bone Symposium: update on osteoporosis. J Clin Densitom (2009) 0.79
Bone density changes with once weekly risedronate in postmenopausal women. J Clin Densitom (2003) 0.79
Analytic challenges in monitoring vitamin D therapy. Am J Clin Pathol (2007) 0.78
Calcium plus vitamin D supplementation has limited effects on femoral geometric strength in older postmenopausal women: the Women's Health Initiative. Calcif Tissue Int (2011) 0.78
Effect of age on regulation of human osteoclast differentiation. J Cell Biochem (2014) 0.78
Does hormone replacement normalize bone geometry in adolescents with anorexia nervosa? J Bone Miner Res (2014) 0.78
Cranial particulate bone graft ossifies calvarial defects by osteogenesis. Plast Reconstr Surg (2012) 0.77
Gene expression changes in an in vitro model of chondroinduction: a comparison of two methods. Wound Repair Regen (2003) 0.77
Fate of a chimeric joint construct in an ectopic site in SCID mice. Cell Transplant (2004) 0.77
Altered expression of connective tissue genes in postnatal chondroinduced human dermal fibroblasts. Connect Tissue Res (2003) 0.77
Vitamin D metabolism and action in human marrow stromal cells: effects of chronic kidney disease. J Steroid Biochem Mol Biol (2012) 0.77
Dysregulated in vitro hematopoiesis, radiosensitivity, proliferation, and osteoblastogenesis with marrow from SAMP6 mice. Exp Hematol (2012) 0.76
Calcium plus vitamin D supplementation and height loss: findings from the Women's Health Initiative Calcium and Vitamin D clinical trial. Menopause (2016) 0.75
Wnt pathway regulation by demineralized bone is approximated by both BMP-2 and TGF-β1 signaling. J Orthop Res (2012) 0.75
Osteoclastic bone resorption around intraosseous screws in rat and pig mandibles. Microsc Res Tech (2003) 0.75
The spectrum of renal bone disease: introduction. Semin Nephrol (2009) 0.75
Mechanisms of osteoinduction/chondroinduction by demineralized bone. J Craniofac Surg (2009) 0.75
Inlay cranioplasty: an experimental comparison of particulate graft versus bone dust. Plast Reconstr Surg (2010) 0.75